Clinical Publications

Clinical Publications

Progenity conducts and publishes ongoing research, to encourage open sharing of ideas and information that can lead to better patient care.

At inception, the ability to detect aneuploidy in twin pregnancies using cell-free DNA (cfDNA) was rightfully doubted. But there is now increasing data supporting the use of cfDNA screening for twin pregnancies.

Historical data indicated 1 in 12 women were at risk for hereditary cancer. New data suggest we were significantly underestimating this risk. Find out more about the new data here.

Innatal noninvasive prenatal screening is backed by a peer-reviewed, high powered study.

Our ingestible technologies show promising results that could transform clinical diagnostics and therapeutics for GI disease. Read more about the difficulties in diagnosing GI disease and how our technology is an expected solution.

At Digestive Disease Week® 2019 in San Diego, we presented results from three proof-of-concept studies that represent potential breakthrough systems for diagnosing, treating, and monitoring digestive diseases through ingestible technologies.

Guidelines for identifying hemoglobinopathy carriers recommend genotyping only for certain patients. But these results show that concurrent testing may be the way to go.

Zoom in from full chromosome to single nucleotide with a new application for cell-free DNA (cfDNA) technology. Expand your patients’ prenatal options with the Resura® Prenatal Test.

Did you know maternal blood chimerism can be detected during cell-free DNA screening? Neither did we, until this happened.

We collaborated with Geisinger to perform the first study using primary data to uncover the economic burden of preeclampsia.

Sickle cell anemia (Hb S) is a classic study in carrier status and recessive inheritance, but the beta-hemoglobinopathies are far more complex than they seem. This study highlights the diversity within this group of disorders, and within the ethnicities at risk.